Literature DB >> 24980715

Metabolomic biomarkers: their role in the critical path.

Laura K Schnackenberg1, Richard D Beger2.   

Abstract

Global metabolic profiling is being applied to identify biomarkers of health. Some small molecules are exquisitely sensitive indicators of health status. Metabolic profiling analyses are being used to determine biomarkers of drug safety and effectiveness as well as disease diagnosis and prognosis including organ transplant rejection. To understand the mechanism(s) of drug toxicity and disease, a systems biology approach that considers the information generated from metabolic profiling, genetics, transcriptomics and proteomics research paradigms is necessary. This will allow for a better understanding of the mechanism(s) of drug interactions and disease while possibly identifying susceptible populations, an important goal in the move toward personalized medicine.: © Published by Elsevier Ltd.

Entities:  

Year:  2007        PMID: 24980715     DOI: 10.1016/j.ddtec.2007.10.012

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  5 in total

1.  A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica.

Authors:  Teklab Gebregiworgis; Helle H Nielsen; Chandirasegaran Massilamany; Arunakumar Gangaplara; Jay Reddy; Zsolt Illes; Robert Powers
Journal:  J Proteome Res       Date:  2016-01-27       Impact factor: 4.466

2.  Proton Nuclear Magnetic Resonance (¹H-NMR)-Based Metabolomic Evaluation of Human Renal Allografts from Donations After Circulatory Death.

Authors:  Zijie Wang; Haiwei Yang; Chunchun Zhao; Jifu Wei; Junsong Wang; Zhijian Han; Jun Tao; Zhen Xu; Xiaobin Ju; Ruoyun Tan; Min Gu
Journal:  Med Sci Monit       Date:  2017-11-17

3.  Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington's disease peripheral blood samples.

Authors:  Anastasios Mastrokolias; Rene Pool; Eleni Mina; Kristina M Hettne; Erik van Duijn; Roos C van der Mast; GertJan van Ommen; Peter A C 't Hoen; Cornelia Prehn; Jerzy Adamski; Willeke van Roon-Mom
Journal:  Metabolomics       Date:  2016-07-27       Impact factor: 4.290

Review 4.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

Review 5.  Pharmacometabolomics in Early-Phase Clinical Development.

Authors:  T Burt; S Nandal
Journal:  Clin Transl Sci       Date:  2016-04-29       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.